The Danish National Multiple Myeloma Registry

Peter Gimsing; Morten Orebo Holmström; Tobias Wirenfelt Klausen; Niels Frost Andersen; Henrik Gregersen; Robert Schou Pedersen; Torben Plesner; Per Trøllund Pedersen; Mikael Frederiksen; Ulf Christian Frølund; Carsten Helleberg; Annette Vangsted; Peter de Nully Brown; Niels Abildgaard

doi:10.2147/CLEP.S99463

The Danish National Multiple Myeloma Registry

Peter Gimsing, Morten Orebo Holmström, Tobias Wirenfelt Klausen, Niels Frost Andersen, Henrik Gregersen, Robert Schou Pedersen, Torben Plesner, Per Trøllund Pedersen, Mikael Frederiksen, Ulf Christian Frølund, Carsten Helleberg, Annette Vangsted, Peter de Nully Brown, Niels Abildgaard

Department of Clinical Medicine

19 Citations (Scopus)

Abstract

AIM: The Danish National Multiple Myeloma Registry (DMMR) is a population-based clinical quality database established in January 2005. The primary aim of the database is to ensure that diagnosis and treatment of plasma cell dyscrasia are of uniform quality throughout the country. Another aim is to support research. Patients are registered with their unique Danish personal identification number, and the combined use of DMMR, other Danish National registries, and the Danish National Cancer Biobank offers a unique platform for population-based translational research.

STUDY POPULATION: All newly diagnosed patients with multiple myeloma (MM), smoldering MM, solitary plasmacytomas, and plasma cell leukemia in Denmark are registered annually; ~350 patients. Amyloid light-chain amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), monoclonal gammopathy of undetermined significance and monoclonal gammopathy of undetermined significance with polyneuropathy have been registered since 2014.

MAIN VARIABLES: The main registered variables at diagnosis are patient demographics, baseline disease characteristics, myeloma-defining events, clinical complications, prognostics, first- and second-line treatments, treatment responses, progression free, and overall survival.

DESCRIPTIVE DATA: Up to June 2015, 2,907 newly diagnosed patients with MM, 485 patients with smoldering MM, 64 patients with plasma cell leukemia, and 191 patients with solitary plasmacytomas were registered. Registration completeness of new patients is ~100%. A data validation study performed in 2013-2014 by the Danish Myeloma Study Group showed >95% data correctness.

CONCLUSION: The DMMR is a population-based data validated database eligible for clinical, epidemiological, and translational research.

Original language	English
Journal	Clinical Epidemiology
Volume	8
Pages (from-to)	583-587
Number of pages	5
ISSN	1179-1349
DOIs	https://doi.org/10.2147/CLEP.S99463
Publication status	Published - 25 Oct 2016

Keywords

Review
Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2147/CLEP.S99463Licence: CC BY-NC

Cite this

@article{9830c6fb75fd4fea9ef6c219f5f124b6,

title = "The Danish National Multiple Myeloma Registry",

abstract = "AIM: The Danish National Multiple Myeloma Registry (DMMR) is a population-based clinical quality database established in January 2005. The primary aim of the database is to ensure that diagnosis and treatment of plasma cell dyscrasia are of uniform quality throughout the country. Another aim is to support research. Patients are registered with their unique Danish personal identification number, and the combined use of DMMR, other Danish National registries, and the Danish National Cancer Biobank offers a unique platform for population-based translational research.STUDY POPULATION: All newly diagnosed patients with multiple myeloma (MM), smoldering MM, solitary plasmacytomas, and plasma cell leukemia in Denmark are registered annually; ~350 patients. Amyloid light-chain amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), monoclonal gammopathy of undetermined significance and monoclonal gammopathy of undetermined significance with polyneuropathy have been registered since 2014.MAIN VARIABLES: The main registered variables at diagnosis are patient demographics, baseline disease characteristics, myeloma-defining events, clinical complications, prognostics, first- and second-line treatments, treatment responses, progression free, and overall survival.DESCRIPTIVE DATA: Up to June 2015, 2,907 newly diagnosed patients with MM, 485 patients with smoldering MM, 64 patients with plasma cell leukemia, and 191 patients with solitary plasmacytomas were registered. Registration completeness of new patients is ~100%. A data validation study performed in 2013-2014 by the Danish Myeloma Study Group showed >95% data correctness.CONCLUSION: The DMMR is a population-based data validated database eligible for clinical, epidemiological, and translational research.",

keywords = "Review, Journal Article",

author = "Peter Gimsing and Holmstr{\"o}m, {Morten Orebo} and Klausen, {Tobias Wirenfelt} and Andersen, {Niels Frost} and Henrik Gregersen and Pedersen, {Robert Schou} and Torben Plesner and Pedersen, {Per Tr{\o}llund} and Mikael Frederiksen and Fr{\o}lund, {Ulf Christian} and Carsten Helleberg and Annette Vangsted and {de Nully Brown}, Peter and Niels Abildgaard",

year = "2016",

month = oct,

day = "25",

doi = "10.2147/CLEP.S99463",

language = "English",

volume = "8",

pages = "583--587",

journal = "Clinical Epidemiology",

issn = "1179-1349",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - The Danish National Multiple Myeloma Registry

AU - Gimsing, Peter

AU - Holmström, Morten Orebo

AU - Klausen, Tobias Wirenfelt

AU - Andersen, Niels Frost

AU - Gregersen, Henrik

AU - Pedersen, Robert Schou

AU - Plesner, Torben

AU - Pedersen, Per Trøllund

AU - Frederiksen, Mikael

AU - Frølund, Ulf Christian

AU - Helleberg, Carsten

AU - Vangsted, Annette

AU - de Nully Brown, Peter

AU - Abildgaard, Niels

PY - 2016/10/25

Y1 - 2016/10/25

N2 - AIM: The Danish National Multiple Myeloma Registry (DMMR) is a population-based clinical quality database established in January 2005. The primary aim of the database is to ensure that diagnosis and treatment of plasma cell dyscrasia are of uniform quality throughout the country. Another aim is to support research. Patients are registered with their unique Danish personal identification number, and the combined use of DMMR, other Danish National registries, and the Danish National Cancer Biobank offers a unique platform for population-based translational research.STUDY POPULATION: All newly diagnosed patients with multiple myeloma (MM), smoldering MM, solitary plasmacytomas, and plasma cell leukemia in Denmark are registered annually; ~350 patients. Amyloid light-chain amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), monoclonal gammopathy of undetermined significance and monoclonal gammopathy of undetermined significance with polyneuropathy have been registered since 2014.MAIN VARIABLES: The main registered variables at diagnosis are patient demographics, baseline disease characteristics, myeloma-defining events, clinical complications, prognostics, first- and second-line treatments, treatment responses, progression free, and overall survival.DESCRIPTIVE DATA: Up to June 2015, 2,907 newly diagnosed patients with MM, 485 patients with smoldering MM, 64 patients with plasma cell leukemia, and 191 patients with solitary plasmacytomas were registered. Registration completeness of new patients is ~100%. A data validation study performed in 2013-2014 by the Danish Myeloma Study Group showed >95% data correctness.CONCLUSION: The DMMR is a population-based data validated database eligible for clinical, epidemiological, and translational research.

AB - AIM: The Danish National Multiple Myeloma Registry (DMMR) is a population-based clinical quality database established in January 2005. The primary aim of the database is to ensure that diagnosis and treatment of plasma cell dyscrasia are of uniform quality throughout the country. Another aim is to support research. Patients are registered with their unique Danish personal identification number, and the combined use of DMMR, other Danish National registries, and the Danish National Cancer Biobank offers a unique platform for population-based translational research.STUDY POPULATION: All newly diagnosed patients with multiple myeloma (MM), smoldering MM, solitary plasmacytomas, and plasma cell leukemia in Denmark are registered annually; ~350 patients. Amyloid light-chain amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), monoclonal gammopathy of undetermined significance and monoclonal gammopathy of undetermined significance with polyneuropathy have been registered since 2014.MAIN VARIABLES: The main registered variables at diagnosis are patient demographics, baseline disease characteristics, myeloma-defining events, clinical complications, prognostics, first- and second-line treatments, treatment responses, progression free, and overall survival.DESCRIPTIVE DATA: Up to June 2015, 2,907 newly diagnosed patients with MM, 485 patients with smoldering MM, 64 patients with plasma cell leukemia, and 191 patients with solitary plasmacytomas were registered. Registration completeness of new patients is ~100%. A data validation study performed in 2013-2014 by the Danish Myeloma Study Group showed >95% data correctness.CONCLUSION: The DMMR is a population-based data validated database eligible for clinical, epidemiological, and translational research.

KW - Review

KW - Journal Article

U2 - 10.2147/CLEP.S99463

DO - 10.2147/CLEP.S99463

M3 - Journal article

C2 - 27822103

SN - 1179-1349

VL - 8

SP - 583

EP - 587

JO - Clinical Epidemiology

JF - Clinical Epidemiology

ER -

The Danish National Multiple Myeloma Registry

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this